Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3350/cmh.2024.0817 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
siRNA Treatment Enhances Collagen Fiber Formation in Tissue-Engineered Meniscus via Transient Inhibition of Aggrecan Production.
Bioengineering (Basel)
December 2024
Meinig of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.
The complex collagen network of the native meniscus and the gradient of the density and alignment of this network through the meniscal enthesis is essential for the proper mechanical function of these tissues. This architecture is difficult to recapitulate in tissue-engineered replacement strategies. Prenatally, the organization of the collagen fiber network is established and aggrecan content is minimal.
View Article and Find Full Text PDFPortal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Centre for Liver and Digestive Diseases (CIBERehd).
Gastroenterol Hepatol
January 2025
Servicio de Hepatología, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, España. Electronic address:
Portal hypertension is a hemodynamic abnormality that complicates the course of cirrhosis, as well as other diseases that affect the portal venous circulation. The development of portal hypertension compromises prognosis, especially when it rises above a certain threshold known as clinically significant portal hypertension (CSPH). In the consensus conference on Portal Hypertension promoted by the Spanish Association for the Study of the Liver and the Hepatic and Digestive diseases area of the Biomedical Research Networking Center (CIBERehd), different aspects of the diagnosis and treatment of portal hypertension caused by cirrhosis or other diseases were discussed.
View Article and Find Full Text PDFOptimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease.
Am J Gastroenterol
January 2025
Division of Endocrinology, Gerontology and Metabolism Stanford University School of Medicine.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important public health threat, potentially leading to chronic liver disease and liver cancer. Current guidelines recommend using the FIB-4 score for initial identification of subjects at risk of future complications. We formulate a novel population screening strategy based on the Steatosis-Associated Fibrosis Estimator (SAFE) score, recently developed for MASLD risk stratification in primary care.
View Article and Find Full Text PDFLubiprostone Reduces Fat Content on MRI-PDFF in Patients With MASLD: A 48-Week Randomised Controlled Trial.
Aliment Pharmacol Ther
January 2025
Liver Unit, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Article Synopsis
- A 48-week study was conducted to evaluate the safety and effectiveness of the laxative lubiprostone in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), showing promising results.
- Lubiprostone significantly reduced liver fat content compared to placebo, although it did not significantly impact fibrosis scores or serum ALT levels.
- While the treatment was generally tolerated, with only one case of severe diarrhea in the lubiprostone group, further research is needed to confirm its efficacy for MASLD.
Regression of liver fibrosis after seroclearance of hepatitis B surface antigen: a prospective matched case-control study using transient elastography and serum Enhanced Liver Fibrosis test (abridged secondary publication).
Hong Kong Med J
December 2024
Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!